There are only a few immunohistochemical markers that are useful for differentiating thymic carcinomas from type B3 thymomas. The purpose of this study is to examine the additional markers that would be useful for differentiating between thymic carcinoma and thymoma type B3. We performed a tissue microarray analysis of surgically resected thymic tumor specimens from12 cases of thymic carcinoma, 7 cases of type B3 thymoma, and 68 cases of other types of thymoma. Immunostaining using 49 antibodies was scored based on staining intensity and the percentage of cells that stained positive. Seven proteins that were selected by the staining scores, namely, GLUT-1 (167 vs 4), CA-IX (110 vs 15), c-kit (162 vs 44), CD5 (33 vs 0), MUC-1 (54 vs 0), CEA (42 vs 0), and CK18 (110 vs 42), were significantly higher in the thymic carcinomas than in the type B3 thymomas. The staining sensitivity and specificity of the antibodies for thymic carcinoma were GLUT-1, sensitivity 72% and specificity 100%; CA-IX, 58 and 71%; c-kit, 72 and 85%; CD5, 33 and 100%; CK18, 58 and 71%; MUC-1, 25 and 100%; and CEA, 33 and 100%. Glucose transporter 1 (GLUT-1) is the best marker for thymic carcinoma because it had the highest sensitivity and specificity. Positive immunostaining for a combination of three markers, namely, GLUT-1, CD5, and CEA, enabled differentiation of thymic carcinoma with 91.6% sensitivity and 100% specificity. In conclusion, we identified GLUT-1 as an additional marker that will be useful for differentiating thymic carcinoma from type B3 thymoma, especially in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically in thymic tumors.
The thymus is an immune-related organ, whose network-forming epithelial cells are responsible for immature T-cell (thymocyte) growth, development, and differentiation. Thymic epithelial tumors are traditionally classified as thymomas and thymic carcinomas. Thymomas consist of neoplastic epithelial cells and immature T cells intermingled in variable proportions, whereas thymic carcinomas consist of tumor cells similar to carcinomas occurring in other organs with infiltrating mature T cells. However, little is known about the pathogenesis of thymoma or thymic carcinomas.
In 1999, the World Health Organization (WHO) published a classification of thymic epithelial tumors that is based on the morphology of the epithelial cells and the lymphocyte-to-epithelial cell ratio of the tumor. Thymic epithelial tumors are classified into five types: A, AB, B1, B2, and B3. In type A the epithelial cells appear spindle-shaped or oval, whereas in type B they are dendritic or plump, and tumors that combine these two morphologies are designated as type AB. Type B thymomas are subdivided into subtypes B1, B2, and B3, increasing with the ratio of atypia in the neoplastic cells. Type B3 thymoma was predominantly epithelial type, with severe cellular atypia and a few immature T cells around the tumor cells, and was considered to be a borderline malignancy. On the other hand, all thymic carcinomas are classified as type C thymomas. In 2004, the WHO classification of thymic tumors was revised and the term 'type C thymoma' was replaced by 'thymic carcinoma. ' 1,2 The validity of this classification as a prognostic tool is a matter of controversy, even if the preliminary studies are encouraging. It is sometimes difficult to make the differential diagnosis between thymoma type B3 and thymic carcinoma histologically, especially when the biopsy specimen is small. Although immunoreactivity for CD5 and c-kit has been reported as a useful marker for primary thymic carcinoma, but not for thymoma, the positive rate of CD5 and c-kit has been reported to be limited to over 50%; [3] [4] [5] [6] [7] and as not all neoplastic cells in thymic carcinomas stain positive for these markers, [8] [9] [10] [11] it will be necessary to identify other diagnostic markers to make the differential diagnosis more reliable.
In this study, we used a tissue microarray with a large panel of antibodies to identify additional immunohistochemical markers to phenotypically differentiate between thymic carcinomas and type B3 thymomas.
Materials and methods

Case Selection
During the period from January 1992 to December 2006, a total of 94 patients with thymic epithelial tumors were treated at the National Cancer Center Hospital East, Chiba, Japan. All thymic epithelial tumors, with a pathological diagnosis based on the classification schema of the third edition of the WHO classification, were reviewed, and 18 tumors were diagnosed as type A thymoma, 27 as type B1 and 10 as type B2 thymoma, 12 as type AB thymoma, and 18 as thymic carcinoma. The six cases of thymic carcinoma, and four cases of thymoma, for which an adequate tissue specimen was not available for pathological review, were excluded from the study, leaving a total of 84 cases of thymic epithelial tumor for review. The tumors selected for tissue microarray analysis were: 10 cases of type A thymoma, 5 cases of type B1 thymoma, 5 cases of type B2 thymoma, 7 cases of type B3 thymoma, and 12 cases of thymic carcinomas. The 12 cases of thymic carcinoma consisted of 6 cases of keratinizing carcinoma and 6 cases non-keratinizing carcinoma. Representative figures of type B3 thymoma and thymic carcinoma are shown in Figure 1a , b, c, and d.
Pathological Studies
After fixing the specimens with 10% formalin and embedding them in paraffin, serial 4-mm sections were stained using hematoxylin and eosin (H&E). The sections were reviewed by two pathologists (MK, GI), according to the histological criteria described in the WHO classification, and the discrepancies were resolved by joint discussion of the slides while viewing with a multiheaded microscope. In addition to the morphological examination, we examined the sections for the presence of immature T thymocyte using CD99 and terminal deoxynucleotidyl transferase immunostaining.
Construction of Tumor Tissue Microarrays
Tissue microarrays were constructed according to the procedure described in previous reports. [12] [13] [14] Briefly, the most representative tumor areas were carefully selected and marked on the H&E-stained slide to construct the microarrays, and the tissue microarrays were assembled using a tissue arraying instrument (KIN-1; Azumaya, Tokyo, Japan). 15 The microarray system consists of thin-walled stainless steel needles approximately 2 mm in diameter, and a stylet for transferring and removing the contents of the needle. The assembly is held in an x-y position guide that is manually adjusted using digital micrometers. Core samples are retrieved from selected areas of donor tissue and precisely arrayed in a new (recipient) paraffin block. Samples of the specimens were routinely obtained by collecting two replicate core samples of the tumor from different areas. The normal thymus tissue and liver tissue, used as the positive/negative control, were arrayed in sample paraffin blocks.
Antibodies and Immunohistochemical Staining
The 49 antibodies used in this study are listed in Table 1 . Immunohistochemical staining was performed according to the procedure described in a previous report. 13 Tissue microarray donor blocks were cut into 4-mm sections and mounted on silanecoated slides. The sections were then deparaffinized in xylene and dehydrated in a graded alcohol series, and the endogenous peroxidase was blocked using 3% hydrogen peroxide in absolute methyl alcohol. Heat-induced epitope retrieval was performed for 20 minutes at 951C using a 0.02-mol/l concentration of citrate buffer (pH 6.0). After allowing the slides to cool at room temperature for 60 minutes, they were rinsed with deionized water and incubated overnight with the primary antibodies. The slides were then washed thrice with phosphate-buffered saline and incubated with the EnVision þ System-HRP (Dako, Glostrup, Denmark). The reaction products were stained using diaminobenzidine and counterstained using hematoxylin. Some antibodies (Table 1) were used in an automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA) after antigen retrieval by microwave heating and using citrate buffer. Immunostaining was recorded as positive when more than 20% of the cancer cells exhibited intermediate or strong staining (staining intensity ¼ 2, 3).
Immunohistochemical Scoring and Criteria for Positive Staining
The tissue sections were semiquantitatively scored separately for membranous and cytoplasmic staining by light microscopy. Staining scores were calculated by multiplying the percentage of positive tumor cells per slide (0-100%) by the predominant level of staining intensity: 0 ¼ negative, 1 ¼ weak, 2 ¼ intermediate, and 3 ¼ strong. Possible scores ranged from 0 to 300. The scores of two stained samples were averaged, and the result was recorded as score for that tumor. The staining scores obtained for the two samples from the same specimen were calculated. If one sample was lost, the staining score was calculated from the data for the remaining sample alone.
Statistical Analysis
The prism statistical software package (GraphPad Software, San Diego, CA, USA) was used to perform the statistical analyses. The correlations between the thymic carcinoma group and the thymoma group, and the results of immunohistochemical staining were evaluated by the w 2 -test or Fisher's exact test, as appropriate. P-values o0.05 were considered significant. 
Results
Staining Scores for the Thymic Carcinomas and Thymomas
The thymic carcinoma and thymoma scores for staining with each antibody are summarized in Table 2 . Antibodies whose staining score showed the statistical differences between thymic carcinoma and type B3 thymoma were shown in Table 3 .
Cytokeratins Of the 13 cytokeratins tested, the thymic carcinoma scores for CK18 staining were significantly higher (Figure 2a ) than the thymoma type B3 scores (P ¼ 0.0460). The average staining score of thymic carcinomas was 110, as opposed to 42 for type B3 thymomas. The average staining score for CK17 was 137 in the thymic carcinomas and 50 in type B3 thymomas, and the difference was significant (P ¼ 0.0118). However, the average staining score of type A, and type B1, B2 thymomas were 84 and 50; and the statistical difference between the type A thymomas and thymic carcinomas was not significant (P ¼ 0.1627). No significant differences between the thymic carcinomas and type B3 thymomas in the expression of the other cytokeratins were found.
Hypoxia-related markers
The scores of the thymic carcinomas staining for glucose transporter 1 (GLUT-1) and carbonic anhydrase IX (CA-IX) were significantly higher. The GLUT-1 was unequivocally expressed in the membrane and cytoplasmic staining in the tumor cells. The GLUT-1 staining pattern of the thymic carcinomas tended to be more intensely positive in the central area (arrow) of tumor nests than in the peripheral area (arrow head) (Figure 2b, c) . The average staining score for GLUT-1 was 167 in the thymic carcinomas and 4 in the type B3 thymomas, and the difference was significant (Po0.0001). The CA-IX showed membrane and cytoplasmic staining in the tumor cells. (Figure 2d ). The average staining score for CA-IX was 110 in the thymic carcinomas and 15 in the type B3 thymomas, and the difference was significant (P ¼ 0.0099). 1 ± 01 0 ± 00 0 ± 00 0 ± 00
Cluster differential markers  CD5  0±00  0±00  0±00  33±18  CD10  6±04  3±03  0±00  42±29  CD15  157±46  13±08  0±00  45±21  CD20 12 ± 10 13 ± 09 0 ± 00 0 ± 00 CD30 0 ± 00 0 ± 00 0 ± 00 0 ± 00 CD117 (c-kit) 2 ± 00 8 ± 00 44 ± 00 162 ± 00 CD133 0 ± 00 0 ± 00 0 ± 00 0 ± 00 221±21  169±16  150±15  179±19  E-cadherin  224±20  111±29  159±23  253±18  CD56  2±01  0±00  0±00  10±07  CD29 290 Mucin-related proteins Muc-1 0±00 0±00 0±00 54±00 Muc-2 19±00 0±00 0±00 0±00 Muc-5 0±00 0±00 0±00 8±00 Muc-6 0 ± 00 1 ± 00 0 ± 00 3 ± 00 M-CCMC-1 0 ± 00 0 ± 00 0 ± 00 0 ± 00
Adhesion molecules b-Catenin
Mesothelium-associated markers Podoplanin 2±01 31±24 87±29 0±00 Calretinin 12±05 0±00 21±14 60±33
Hypoxic markers CA-IX 0 ± 00 0 ± 00 15 ± 11 110 ± 30 GULT-1 7 ± 07 0 ± 00 4 ± 03 167 ± 23
Extracellular matrix
Laminin-5 7±07 0±00 0±00 12±07 
Cluster differential markers
The average staining score for c-kit (CD117) was 162 in the thymic carcinomas and 44 in the type B3 thymomas, and the difference was significant (Po0.0056) (Figure 2e ). The average staining score for CD5 was 33 in the thymic carcinomas ( Figure 2f ) and 0 in all of the types of thymomas, and the difference was statistically significant between thymic carcinomas and all types of thymomas (Po0.0001).
Mucin-related proteins and adhesion molecules
The average staining score for MUC-1 was 54 in the thymic carcinomas and 0 in the type B3 thymomas, and the average staining score for CEA was 42 in thymic carcinomas and 0 in the type B3 thymomas. The scores for both MUC-1 and CEA were the significantly higher in the thymic carcinomas than in all of the types of thymomas (Po0.0001) (Figure 2g , h).
Mesothelium-associated markers
Podoplanin was mainly expressed on the membranous reaction of the tumor cells in the type B3 thymomas and in one case of type B2 thymoma. The average staining score for podoplanin was 87 in the type B3 thymomas, whereas the staining score was 0 in every case of thymic carcinoma, and the difference was significant (Po0.0001). The average staining score for calretinin was 60 in the thymic carcinomas and 21 in type B3 thymoma, but the difference was not significant.
Other antibodies
We evaluated the expression of 42 other biological markers, but no differences in expression were found between the thymic carcinomas and type B3 thymomas.
Sensitivity and Specificity of Positive Immunostaining for GLUT-1, CA-IX, c-kit, CD5, CK18, MUC-1, and CEA for Thymic Carcinoma
We then evaluated the sensitivity and specificity of positive immunostaining for these seven markers in thymic carcinoma, and the results are shown in Table 4 . GLUT-1, CD5, MUC-1, and CEA showed 100% specificity for thymic carcinoma, and GLUT-1, CA-IX, c-kit, and CK18 displayed higher sensitivity. The GLUT-1 showed the highest sensitivity and specificity in these seven markers.
We selected the four markers whose positive immunohistochemical staining showed 100% specificity for thymic carcinoma: GLUT-1, CD5, MUC-1, and CEA, and validated their immunoreactivity in 12 cases of the thymic carcinoma (Table 5) . A total of 8 of the 12 cases of thymic carcinoma were GLUT-1 positive, and 11 cases were positive for GLUT-1, CD5, and/or CEA. Case no. 9 did not show reactivity for any markers. Immunostaining of a combination of three markers, GLUT-1, CD5, and CEA, yielded 91.6% sensitivity and 100% specificity for thymic carcinoma.
Discussion
The results of this study showed that the seven markers selected, that is, GLUT-1, CA-IX, c-kit, CD5, MUC-1, CEA, and CK18, were useful for differentiating between type B3 thymoma and thymic carcinoma. Two of these markers, c-kit and CD5, have already been shown in many publications. 4, 3, 7, 5, 9, 8 Among these 'positive' thymic carcinoma markers identified in the current study, GLUT-1 may be one of the best markers for diagnosing thymic carcinoma for the following reasons. First, GLUT-1 is the marker, which showed the highest sensitivity and specificity for thymic carcinoma (Table 4) . The results of this study showed that 72.7% of the thymic carcinoma stained positive for GLUT-1 as opposed to 0% of the type B3 thymoma. The staining pattern in thymic carcinoma tended to more intense in the central area of the tumor nests than in the peripheral area (Figure 2b ). The average staining score for GLUT-1 (167 ± 23) was high, and much higher than that for CD5 (33±18), which is a well-known thymic carcinoma marker.
Glucose transporter 1 is thought to be a possible intrinsic marker of hypoxia, and the expression of GLUT-1 has been found to be regulated by hypoxia in a HIF-1-dependent way. 16, 17 Glucose transporter 1 is one of 14 members of the mammalian facilitative glucose transporter (GLUT) family of passive carriers that function as an energyindependent system for transport of glucose down a concentration gradient. 18, 19 GLUT-1 is expressed in a variety of carcinomas, including carcinoma of the breast, head and neck, ovary, renal cell carcinoma, lung, and malignant pleural mesothelioma. [20] [21] [22] [23] [24] [25] [26] Positron emission tomography (PET) imaging using [18F]2-fluoro-2-deoxy-D-glucose (FDG) has Immunostaining for CA-IX, 16, 32 another hypoxic marker and a major downstream target of HIF-1a, was also significantly stronger in the thymic carcinomas (staining score: 110), the same as immunostaining for GLUT-1, but its specificity was lower (58% of thymic carcinomas and 28% of type B3 thymomas stained positive for CA-IX).
The fact that the CA-IX score in other types of thymomas was 0, suggests that a hypoxic microenvironment is a specific characteristic of thymic carcinomas as compared with thymomas.
MUC-1 and CEA showed 100% sensitivity for thymic carcinoma. Both markers might be suitable for making the differential diagnosis, but only 33.3 and 25.0%, respectively, of the thymic carcinoma stained positive and the staining scores were lower than for GLUT-1. In view of these low staining scores, these markers alone may not be suitable for use in small biopsy specimens, such as those obtained by needle biopsy.
Previous studies reported CD5-positive rates of 50-100%, 9, 8, 11, 33 however, our study shows the lower CD5-positive rate (33%). This would be explained by a smaller tissue of tissue microarray. c-kit (CD117) has been reported to be a useful marker for the diagnosis of thymic carcinoma. 5, 9 Previous studies reported positive immunoreactivity for c-kit in 65-91% of thymic carcinomas, as opposed to 0-5% of thymoma. 5, 9, 32, 34 In our study, staining for c-kit was only focally weakly positive in 2 of the 7 cases of type B3 thymoma, and was more extensively expressed in 8 of the 11 cases of thymic carcinoma.
The staining score for CK18 was significantly higher in the thymic carcinomas, consistent with a previous report. 35 Fukai et al showed that CK18 was expressed to a greater extent on the epithelium of thymic carcinomas than on the epithelium of thymomas, including types A, B1, B2, and AB. In their study, although thymic carcinoma shows 33% of diffuse-positive staining reaction of tumor cells with CK18, but none of the types of thymoma show the diffuse reaction. They suggested that the CK18-positive epithelial cells in thymomas may transform into thymic carcinoma cells under certain conditions.
Podoplanin is expressed in normal tissue, including lymphatic endothelium and mesothelium, and in neoplasms, including pulmonary squamous cell carcinomas and malignant mesothelioma. 36, 37 In this study, 57.1% of the type B3 thymomas stained positive for podoplanin, whereas none of the thymic carcinomas reacted with the antibody. This finding is very interesting, and an analysis after accumulation of additional cases is necessary.
When it is difficult to make the differential diagnosis with a single antibody, it is helpful to use a combination of antibodies. 10, 38 In this study, combined use of the three antibodies that yielded 100% specificity for thymic carcinoma, that is, the antibodies for GLUT-1, CD5, and CEA, provided 91.6% sensitivity. Thus, combined use of these three antibodies should be useful for differentiating between thymic carcinoma and type B3 thymoma in biopsy specimens that have been crushed or are otherwise difficult to examine morphologically.
In conclusion, we found that immunostaining for GLUT-1, CA-IX, c-kit, CD5, CK18, MUC-1, and CEA enables differential diagnosis between thymic carcinoma and thymoma type B3. The combination of positive immunostaining for GLUT-1, CD5, and CEA yielded 91.6% sensitivity and 100% specificity for thymic carcinoma. A prospective study of a larger number of cases is required to define the expression of these molecules more precisely in order to enable pathologists to reliably differentiate between thymic carcinoma and type B3 thymoma.
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